Business Description
Psyence Biomedical Ltd. is a Toronto-based company focused on developing plant-derived medicines that use naturally sourced psilocybin to help patients in palliative care cope with anxiety, depression, grief, and similar conditions tied to a terminal cancer diagnosis. Its main treatment, PEX010, is currently being tested in a Phase IIb clinical trial through a partnership with iNGENu Pty Ltd, exploring how psilocybin-assisted therapy can support people living with incurable cancer. The company also works with PsyLabs on the production of Ibogaine and operates as part of the wider Psyence Group Inc.
